ClinicalTrials.gg
RecruitingNCT06295952Updated Mar 4, 2026

A Study of Pasireotide in People With Prolactinoma

A Phase 2 interventional study of Pasireotide and SF-36 and HADS in Prolactin-Producing Pituitary Tumor, sponsored by Memorial Sloan Kettering Cancer Center. Recruiting at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-04.

Sponsored by Memorial Sloan Kettering Cancer Center · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies testing pasireotide in Pituitary Neoplasms — 1 open to participants now, 1 under way, none of them phase 3. pasireotide · Pituitary Neoplasms.

Planned enrollment
8th of 10
10 · median 51
Started
2024
the only one that year
Phase 2
7 of 10
1 open now
Registered
10th of 10
by date
Lead sponsor
1 of 10
Memorial Sloan Kettering Cancer Center

Among the 10 studies testing pasireotide in Pituitary Neoplasms, this one is the 8th largest by planned enrollment, is the only one that started in 2024, is one of 7 in phase 2, and was the 10th registered.

Pituitary Neoplasms

200 studies on the registry are indexed under Pituitary Neoplasms; 51 are open to participants now.

Browse Pituitary Neoplasms studies →

Open to participants now

1 of the 10 studies testing pasireotide in Pituitary Neoplasms is open now, in 1 country.

By country, each count listing its studies:

About pasireotide

pasireotide: first FDA approval 2012 (SIGNIFOR), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 36 Pituitary Neoplasms studies recruiting now, 14 (39%) set no upper age limit and 10 (28%) stop at 75 or younger; 6 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing pasireotide in Pituitary Neoplasms, or all of them as a file.
02

Study summary

The researchers are doing this study to find out whether pasireotide is an effective treatment for people with prolactinoma who cannot receive dopamine agonist therapy. Another purpose of this study is to find out whether pasireotide is a safe treatment for people with prolactinoma.

03

Conditions studied

  • Prolactin-Producing Pituitary Tumor

Browse trials for

Keywords

  • pasireotide
  • dopamine agonist
  • 23-371
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18 or older
  2. Male and female patients with prolactinomas with at least one of the following criteria:

    • Clinical intolerance due to adverse events on DA treatment, preventing continued treatment.
    • to DA treatment (e.g., patients requiring dopamine antagonist therapy or other therapy that is contraindicated).
    • Tumor resistance to DA, defined as \<50% decrease in longest diameter, or progression in tumor size and/or lack of prolactin normalization with at least 2 mg per week, or maximally tolerated dose, of cabergoline or bromocriptine. Patients with a partial response to DA, including a prolactin reduction but not normalization on treatment, will be included, and will continue DA during the study.
  3. Patients are not considered candidates for surgery (e.g., poor surgical candidates, inoperable tumors, patients who refuse surgical treatment, or for whom surgery is deemed not appropriate treatment).
  4. For patients with a history of pituitary radiation, the following criteria must be present:

    • At least 6 months must have elapsed from the time of the most recent radiation treatment to the time of enrollment, and
    • Stable or up trending serum prolactin levels and/or evidence of tumor growth since completion of radiation.
  5. At least 8 weeks washout of prior first-generation somatostatin receptor ligand therapy (octreotide or lanreotide).
  6. Patients on temozolomide will need a of at least 3 weeks.
  7. Patients on carboplatin, cisplatin or etoposide will need a washout period of at least 4 weeks.
  8. Patients on protein kinase inhibitors (e.g., everolimus, lapatinib) will need a washout period of at least 5 half-lives or 2 weeks, whichever in longer.
  9. In general, at least 4 weeks must have elapsed from any other anticancer drug therapy (e.g., bevacizumab).
  10. Stable or lower dose of DA (cabergoline or bromocriptine) for at least one month for those patients continuing DA treatment, i.e. DA dose may not be escalated during trial enrollment.
  11. Screening laboratory values must meet the following criteria:

    • WBC ≥ 2000/μL
    • Neutrophils ≥ 1500/μL
    • ≥ 100 x103/μL
    • > 9.0 g/dL
    • /ALT ≤ 3 x
    • Total ≤ 1.5 x ULN (except subjects with Gilbert Syndrome, who can have total bilirubin \< 3.0 mg/dL)
    • Serum creatinine ≤ 1.5 x ULN or (CrCl) ≥ 40 mL/min using the Cockcroft-Gault formula
  12. Performance Status (KPS) 70 or above
  13. Measurable tumor by V1.1 criteria, ≥ 10 mm.
  14. Women of (WOCBP) must use appropriate methods of while participating in the trial until 30 days after the follow-up period.

    • WOCBP is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not . Menopause is defined clinically as 12 months of amenorrhea in a woman over 45 in the absence of other biological or physiological causes. Women who are not of childbearing potential are not required to use contraception.
    • Women of childbearing potential must have a negative serum or urine pregnancy test upon study entry.
  15. Men who are sexually active with women of childbearing potential must use adequate contraception while participating in the trial. Men who are surgically sterile or azoospermia do not require contraception.

Exclusion criteria

Exclusion Criteria:

  1. Additional pituitary tumor directed therapy, including temozolomide, everolimus, lapatinib, or cytotoxic chemotherapy
  2. Concurrent except non-melanoma skin cancer
  3. Any pituitary surgery within 14 days of enrollment.
  4. Patients with poorly controlled diabetes as defined by >9% or not optimally treated for diabetes mellitus as judged by the investigator
  5. Patients who are not euthyroid as judged by the investigator
  6. Patient with liver disease such as cirrhosis, chronic active hepatitis, or chronic persistent hepatitis, or patients with serum and/or AST >3x , or total >1.5 x ULN
  7. Patients with > 500 ms
  8. History of intolerance or resistance to pasireotide
  9. Women who are pregnant or breast-feeding
  10. Inability to undergo radiographic surveillance
  11. Inability to provide
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Pasireotide

    All patients will initiate open-label treatment with pasireotide LAR on week 1 in the outpatient setting. Pasireotide will be initiated at 40 mg IM one time dose and if tolerated dose will be increased to 60 mg IM every 4 weeks +/-7 days. Additional dose adjustments will be allowed as per PI judgement, based on response and tolerability. Administration of pasireotide will align with package inset. Patients must return to the study center every 28 days (+/- 7 days) to receive study medication and for evaluation.

    Drug: Pasireotide · Other: SF-36 and HADS

Interventions

  • Pasireotide will be initiated at 40 mg IM one time dose and if tolerated dose will be increased to 60 mg IM every 4 weeks +/-7 days.

  • OtherSF-36 and HADS

    Baseline assessment will be conducted within 30 days of starting treatment, week 12, 24 and week 28.

06

What researchers measure

Primary outcomes

  1. biochemical response rate

    response rate as defined by a normal serum prolactin concentration (\<18.0 ng/ml for a male and \< 29.0 ng/ml for a female

    Time frame: within 24 weeks of treatment

Secondary outcomes

  1. radiographic response

    RECIST criteria, V1.1 (30% decrease in longest tumor diameter)

    Time frame: within 24 weeks of treatment

07

Study locations

7 of 7 sites recruiting
  • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
    Basking Ridge, New Jersey 07920, United States
    Recruiting
    • Eliza Geer, MD · Contact646-608-3797
  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
    Middletown, New Jersey 07748, United States
    Recruiting
    • Eliza Geer, MD · Contact646-608-3797
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities)
    Montvale, New Jersey 07645, United States
    Recruiting
    • Eliza Geer, MD · Contact646-608-3797
  • Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities)
    Commack, New York 11725, United States
    Recruiting
    • Eliza Geer, MD · Contact646-608-3797
  • Memorial Sloan Kettering Westchester (Limited Protocol Activities)
    Harrison, New York 10604, United States
    Recruiting
    • Eliza Geer, MD · Contact646-608-3797
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
    Recruiting
    • Eliza Geer, MD · Contact646-608-3797
    • Andrew Lin, MD · Contact212-639-8392
  • Memorial Sloan Kettering Nassau (Limited Protocol Activities)
    Uniondale, New York 11553, United States
    Recruiting
    • Eliza Geer, MD · Contact646-608-3797
08

References and documents

Individual participant data

Plan to share: Yes — Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2024 (actual). Primary completion is estimated for Feb 2027, 36 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 28, 2024
First posted
Mar 6, 2024
StartActual
Feb 27, 2024
Primary completionEst.
Feb 2027
CompletionEst.
Feb 2027
Last update
Mar 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06295952
Collaborators
RECORDATI GROUP
Responsible party
Sponsor
First posted
Mar 6, 2024
Start date
Feb 27, 2024
Primary completion
Feb 2027 (estimated)
Completion
Feb 2027 (estimated)
Last update
Mar 4, 2026

Study contacts

Eliza Geer, MD
Contact
geere@mskcc.org
646-608-3797
Andrew Lin, MD
Contact
212-639-8392
Eliza Geer, MD
principal investigator · Memorial Sloan Kettering Cancer Center

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pasireotide

Start the discussion